| # | Drug | Count |
|---|---|---|
| 0 | RITUXIMAB | 405 |
| 1 | CYCLOPHOSPHAMIDE | 265 |
| 2 | CYCLOPHOSPHAMIDE FOR INJECTION | 265 |
| 3 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 265 |
| 4 | DOXORUBICIN | 242 |
| 5 | PREDNISONE | 202 |
| 6 | OBINUTUZUMAB | 185 |
| 7 | BENDAMUSTINE HCL | 128 |
| 8 | LENALIDOMIDE | 124 |
| 9 | DEXAMETHASONE | 88 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | DEXAMETHASONE INTENSOL | 1 | 0.0278 |
| 1 | MOSUNETUZUMAB | 21 | 0.0190 |
| 2 | OBINUTUZUMAB | 185 | 0.0109 |
| 3 | HYPOCHLOROUS ACID | 1 | 0.0093 |
| 4 | BENDAMUSTINE HCL | 128 | 0.0082 |
| 5 | TAFASITAMAB-CXIX | 7 | 0.0077 |
| 6 | EPCORITAMAB-BYSP | 10 | 0.0075 |
| 7 | GLOFITAMAB | 16 | 0.0059 |
| 8 | BENDAMUSTINE HYDROCHLORIDE | 47 | 0.0055 |
| 9 | CARMUSTINE | 21 | 0.0045 |
| # | Drug class | Count |
|---|---|---|
| 0 | CD20-directed Cytolytic Antibody [EPC] | 406 |
| 1 | Corticosteroid [EPC] | 301 |
| 2 | Alkylating Drug [EPC] | 281 |
| 3 | Thalidomide Analog [EPC] | 124 |
| 4 | Platinum-based Drug [EPC] | 122 |
| 5 | Topoisomerase Inhibitor [EPC] | 80 |
| 6 | Nucleoside Metabolic Inhibitor [EPC] | 75 |
| 7 | Folate Analog Metabolic Inhibitor [EPC] | 43 |
| 8 | Proton Pump Inhibitor [EPC] | 29 |
| 9 | Tumor Necrosis Factor Blocker [EPC] | 29 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Bispecific CD20-directed CD3 T Cell Engager [EPC] | 26 | 0.0064 |
| 1 | Classical Complement Pathway Inhibitor [EPC] | 1 | 0.0031 |
| 2 | Interleukin-5 Antagonist [EPC] | 2 | 0.0029 |
| 3 | CD19-directed Chimeric Antigen Receptor [EPC] | 18 | 0.0018 |
| 4 | CD20-directed Cytolytic Antibody [EPC] | 406 | 0.0013 |
| 5 | Alkylating Drug [EPC] | 281 | 0.0012 |
| 6 | Topoisomerase Inhibitor [EPC] | 80 | 0.0010 |
| 7 | Aryl Hydrocarbon Receptor Agonist [EPC] | 1 | 0.0005 |
| 8 | Platinum-based Drug [EPC] | 122 | 0.0004 |
| 9 | Sphingosine 1-phosphate Receptor Modulator [EPC] | 6 | 0.0004 |